Abstract: The present invention relates to fluorinated and alkylated bile acids.

Abstract: The present invention relates to fluorinated and alkylated bile acids.

Abstract: This disclosure relates to deuterated bile acid compositions. A deuterated compound is selected from the bile acids such as ursodeoxycholic acid (UDCA) and tauroursodeoxycholic acid (TUDCA), and their derivatives, analogs and salts. At least one of the hydrogen atoms in the compound is replaced with deuterium. Also disclosed are pharmaceutical compositions and methods of using the deuterated bile acids.

Abstract: This disclosure relates to deuterated bile acid compositions. A deuterated compound is selected from the disclosed groups of bile acids and their derivatives, analogs and salts. At least one of the hydrogen atoms in the compound is replaced with deuterium.

Abstract: Ursodeoxycholic acid (UDCA) is a bile acid with demonstrated anti-apoptotic activity in both in vitro and in vivo models. Water-soluble prodrugs of UDCA for use in indications where intravenous administration of UDCA may be preferable, such as reducing damage from stroke or acute kidney injury, are disclosed. The disclosed prodrugs showed significant anti-apoptotic activity in a series of in vitro assays.

Abstract: This disclosure relates to deuterated bile acid compositions. A deuterated compound is selected from the disclosed groups of bile acids and their derivatives, analogs and salts. At least one of the hydrogen atoms in the compound is replaced with deuterium.

Abstract: A method of treating or preventing kidney injury includes administering to a patient an effective amount of bile acid, a salt thereof, an analog thereof, or a combination thereof. Methods of preventing or retarding, reversing or abolishing the onset of kidney injuries are discussed. This is achieved through the administration of a bile acid, a salt of the bile acid, an analog of the bile acid or any combinations of these compounds. The bile acid abolishes or interferes or down-regulates metabolic pathways leading to the onset of kidney injury. The bile acid also activates metabolic pathways leading to the slowing or reversing or complete abolishment of the progression of acute kidney injury.

Abstract: This disclosure relates to deuterated bile acid compositions. A deuterated compound is selected from the disclosed groups of bile acids and their derivatives, analogs and salts. At least one of the hydrogen atoms in the compound is replaced with deuterium.

Abstract: Methods of preventing or retarding or reversing or abolishing the onset and preventing the onset of neurodegenerative disease are discussed. This is achieved through the administration of a bile acid, a salt of the bile acid, an analog of the bile acid or any combinations of these compounds. The bile acid abolishes or interferes or down-regulates metabolic pathways leading to the onset of neurodegenerative diseases. The bile acid also activates metabolic pathways leading to the slowing or reversing or complete abolishment of the progression of neurodegenerative disease.